Recent findings suggests that the clinical manifestations of carcinoma, non-small-cell lung were more common in young women and those with smoking history than in elderly and non-smoking ones; there were also differences between smokers and non-smokers regarding gender distribution and site. It might be worthwhile to conduct a large-scale epidemiologic survey on this topic in order to better understand the characteristics of carcinoma, non-small-cell lung.
Sitravatinib did not outperform placebo in terms of PFS or OS. The study was underpowered for OS; however, our results suggest that further larger prospective studies in patients with advanced NSCLC may be warranted.
Lung carcinoma incidence among whites was higher than reported incidence of lung carcinoma among blacks and Hispanics in the US. The leading cause of death from lung carcinoma was lung adenocarcinoma among whites. If these disparities continue, there will be an increasing burden of lung cancer mortality among black and Hispanic Americans.
Sitratavinib decreases PSA levels up to 65% after 2 weeks of continuous dosing, but no significant reductions are seen at steady state. The drug has been found to inhibit TMPRSS8 (also known as MMP17) and also shows some activity against telomerase, a key enzyme involved in cellular division. There is limited evidence that it may also reduce cell growth and migration in vitro. The data suggest that sitravatinib might be useful for the treatment of certain types of breast cancer.
The tolerability profile of sitravatinib appears similar to other agents in this class, including imatinib. Findings from a recent study suggest that sitravatinib may be safer than other agents in this class for the treatment of CML and GIST.
In a recent study, we found significant differences between pre-existing smokers and non-smokers in both carcinoma and non-carcinoma groups. The data obtained suggest that smokers who develop NSCLC may be at higher risk of developing SCC compared with nonsmokers. It seems that smokers who develop carcinoma are more likely to develop SCC than non-smokers. Therefore, it is advisable for physicians to take all smokers into consideration when selecting a treatment strategy for NSCLC patients.
There was no difference between genders in survival rates. Patients younger than 50 years had higher 5-year survival. Male patients over 65 years had better results than females. For carcinoma, NSCLC patients with stage IIIB+IIIC disease, but not with stage I+IIIA disease, had better survival. Survival was worse for patients with a node metastasis.
The mean age at diagnosis was 64 years old (SD = 9.6 years). Most people were diagnosed with early stage disease (stage I and II) although there was a small proportion of late stage disease (stage III and IV). Age did not appear to affect survival, with the exception of older patients who survived longer after diagnosis compared with younger patients.
Sitreavatinib represents a novel oral, small molecule inhibitor of blood vessel formation that has demonstrated potent antiangiogenic properties in preclinical models of solid tumors. Results from a recent clinical trial suggest that further evaluation of sitreavatinib as an antiangiogenic agent alone or in combination with conventional anticancer agents is warranted.
Sitravatinib shows potential for treating cancers with PTEN mutation, especially NSCLC. The most commonly reported side effects in patients treated with sitravatinib include fatigue, nausea, vomiting, diarrhea, constipation, abdominal pain, headache, dizziness, cough, and rash. For those who develop these symptoms while on sitravatinib, they should seek medical attention.